Rebecca Wallings

Indiana University
United States

Elaine Lim on Can Autoimmunity Spark Alzheimer’s Disease?

COMMENT I believe this is among the first, if not the first, large-scale, systematic study of electronic medical records (EHR) testing associations between Alzheimer’s and 26 autoimmune diseases. I found the paper super interesting because several studies have re

Chun Keung Shum

PAPER Buchholz E, Machule ML, Buthut M, Stefanovski L, Rössling R, Prüss H

Overlapping presence of β-amyloid, tau, p-tau, and α-synuclein in skin nerve fibers in Alzheimer's disease.

J Neurol. 2025 Mar 5;272(3):247. PubMed.

PAPER Abdeen AH, Trist BG, Nikseresht S, Harwood R, Roudeau S, Rowlands BD, Kreilaus F, Cottam V, Mor D, Richardson M, Siciliano J, Forkgen J, Schaffer G, Genoud S, Li AA, Proschogo N, Antonio B, Falkenberg G, Brueckner D, Kysenius K, Liddell JR, Fat SC, Wu S, Fifita J, Lockwood TE, Bishop DP, Blair I, Ortega R, Crouch PJ, Double KL

Parkinson-like wild-type superoxide dismutase 1 pathology induces nigral dopamine neuron degeneration in a novel murine model.

Acta Neuropathol. 2025 Mar 5;149(1):22. PubMed.

PAPER Reho P, Kalia V, Jackson GL, Wang F, Eiten E, Brennan K, Brickman AM, Mayeux R, Miller GW, Vardarajan BN, Baccarelli A, Wu H

Preclinical Alzheimer's disease shows alterations in circulating neuronal-derived extracellular vesicle microRNAs in a multiethnic cohort.

Alzheimers Dement. 2025 Mar;21(3):e70050. PubMed.

PAPER Sirerol-Piquer MS, Perez-Villalba A, Duart-Abadia P, Belenguer G, Gómez-Pinedo U, Blasco-Chamarro L, Carrillo-Barberà P, Pérez-Cañamás A, Navarro-Garrido V, Dehay B, Vila M, Vitorica J, Pérez-Sánchez F, Fariñas I

Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species.

Mol Neurodegener. 2025 Mar 5;20(1):26. PubMed.

PAPER Xu J, Su Y, Sha Y, Fu J, Yan T, Xu F, Tang H, Ying Y, Xia Y, Dong Q, Gurol ME, Ni J, Cheng X

Circulating proteomic biomarkers for cerebral amyloid angiopathy screening and risk stratification.

Alzheimers Dement. 2025 Mar;21(3):e70044. PubMed.

PAPER Ma L, Wang Y, Huynh AL, Amadoru S, Wrigley S, Yates P, Masters CL, Goudey B, Jin L, Pan Y

Exploring epidemiological risk factors for cerebral amyloid angiopathy: Considerations for monoclonal antibody therapy in people with Alzheimer's disease.

Alzheimers Dement. 2025 Mar;21(3):e14602. PubMed.

PAPER Chu C, Wang Y, Ma L, Mutimer CA, Ji G, Shi H, Yassi N, Masters CL, Goudey B, Jin L, Pan Y

Developing and validating a prediction tool for cerebral amyloid angiopathy neuropathological severity.

Alzheimers Dement. 2025 Mar;21(3):e14583. PubMed.

PAPER Achouri-Rassas A, Fray S, Said Z, Ben Sassi S, Ben Ali N, Baraket G

Genetic association study between rs2234253 (p.T96K) variant of TREM2 and Alzheimer's disease in a Tunisian population.

Neurol Res. 2025 Mar 5;:1-6. Epub 2025 Mar 5 PubMed.

PAPER Kim SA, Shin D, Ham H, Kim Y, Gu Y, Kim HJ, Na DL, Zetterberg H, Blennow K, Seo SW, Jang H, Precision Medicine Platform for Mild Cognitive Impairment Based on Multi-omics, Imaging, Evidence-Based R&BD (PREMIER) Consortium

Physical Activity, Alzheimer Plasma Biomarkers, and Cognition.

JAMA Netw Open. 2025 Mar 3;8(3):e250096. PubMed.

PAPER D'Aoust T, Clocchiatti-Tuozzo S, Rivier CA, Mishra A, Hachiya T, Grenier-Boley B, Soumaré A, Duperron MG, Le Grand Q, Bouteloup V, Proust-Lima C, Samieri C, Neuffer J, Sargurupremraj M, Chêne G, Helmer C, Thibault M, Amouyel P, Lambert JC, Kamatani Y, Jacqmin-Gadda H, Tregouët DA, Inouye M, Dufouil C, Falcone GJ, Debette S

Polygenic score integrating neurodegenerative and vascular risk informs dementia risk stratification.

Alzheimers Dement. 2025 Mar;21(3):e70014. PubMed.

PAPER Sun J, Chen F, She L, Zeng Y, Tang H, Ye B, Zheng W, Xiong L, Li L, Li L, Yu Q, Chen L, Wang W, Liang G, Zhao X

YOD1 regulates microglial homeostasis by deubiquitinating MYH9 to promote the pathogenesis of Alzheimer's disease.

Acta Pharm Sin B. 2025 Jan;15(1):331-348. Epub 2024 Nov 26 PubMed.

PAPER Lu J, Zhou Q, Zhu D, Song H, Xie G, Zhao X, Huang Y, Cao P, Wang J, Shen X

Drofenine as a Kv2.1 inhibitor alleviated AD-like pathology in mice through Aβ/Kv2.1/microglial NLRP3/neuronal Tau axis.

Acta Pharm Sin B. 2025 Jan;15(1):371-391. Epub 2024 Nov 26 PubMed.